CuraGen Corporation (NASDAQ: CRGN), a biopharmaceutical company, is devoted to improving the lives of patients by developing pharmaceutical products that address medical needs that are currently unmet. The company’s therapeutics are based on the research of novel drug targets and mechanisms that are believed to play a role in underlying diseases. Through its efforts, CuraGen has utilized this research and understanding to develop a pipeline of protein, antibody, and antibody-drug conjugate drugs. For further information, visit the Company’s web site at www.curagen.com.
- 17 years ago
QualityStocks
CuraGen Corporation (NASDAQ: CRGN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…